Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients

BACKGROUND: Antibodies against programmed death 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1) have recently shown promising results in gastric cancer (GC). However, clinicians still lack predictive biomarkers for the efficacy of anti-PD-1 therapy; thus, we investigated the expression of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinhua, Zhang, Huimin, Wang, Minghao, Liu, Hao, Hu, Yanfeng, Lin, Tian, Chen, Hao, Zhao, Mingli, Chen, Tao, Li, Guoxin, Yu, Jiang, Zhao, Liying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990248/
https://www.ncbi.nlm.nih.gov/pubmed/35401534
http://dx.doi.org/10.3389/fimmu.2022.783695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990248/
https://www.ncbi.nlm.nih.gov/pubmed/35401534
http://dx.doi.org/10.3389/fimmu.2022.783695

Ejemplares similares